Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. (Q40926668)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 May 2015

Language	Label	Description	Also known as
English	Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.	scientific article published on 19 May 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

František Štaud

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Daniela Cihalova

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Martina Ceckova

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

19 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

76

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

105-116

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Improving cancer chemotherapy with modulators of ABC drug transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The challenge of exploiting ABCG2 in the clinic.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Principles of CDK regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Cell cycle, CDKs and cancer: a changing paradigm

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Cyclin dependent kinases in cancer: potential for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The CDK inhibitors in cancer research and therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Drug interactions in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Potent interaction of flavopiridol with MRP1

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Targeting multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Utilization of membrane vesicle preparations to study drug–ABC transporter interactions

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40926668&oldid=2204098882"